StockNews.AI
BMY
StockNews.AI
161 days

2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb

1. Bristol Myers Squibb to acquire 2seventy bio for $286 million. 2. The deal represents an 88% premium over 2seventy's recent stock price.

2m saved
Insight
Article

FAQ

Why Bullish?

Acquiring 2seventy bio could enhance BMY's portfolio and market position, similar to past acquisitions that led to stock price gains.

How important is it?

This acquisition supports BMY's growth strategy, influencing investor confidence and share performance.

Why Long Term?

The effects of this acquisition may manifest gradually, improving BMY's product offerings and market share over time.

Related Companies

TSVTJNJAMGN
CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE: BMY) (“BMS”) will acquire all of the outstanding shares of 2seventy bio at a price of $5.00 per share in an all-cash transaction for a total equity value of approximately $286 million, or $102 million net of estimated cash. The deal represents an 88% premium to the closing price of $2.66 on March 7, 2025. “A year ago, 2seventy decided to exc.

Related News